MAP2K7 and hepatocellular carcinoma: Sorafenib inhibits tumor growth in HCC by blocking Raf-1, B-Raf, and Ras/Raf/mitogen-activated protein kinase(MEK)/ERK signaling kinase activity, as well as by inhibiting the angiogenesis-targeting PDGFR-β, VEGFR2, and cKIT [162].